Alkem Laboratories Ltd Share Price (ALKEM)

Alkem Laboratories' Total Shareholder Returns Outpace Earnings Growth - 15 Apr, 2024

Alkem Laboratories has managed to grow its earnings per share at 19% a year, which is close to the annualized share price gain of 22% per year. The TSR of Alkem Laboratories is 191% for the last 5 years, exceeding its share price return.

US FDA Issues Observations on Alkem's Baddi Unit; CFO Confident About Future Product Launches - 12 Apr, 2024

The US FDA has issued a report highlighting procedural errors at Alkem Laboratories' Baddi unit. While analysts believe an OAI classification is possible, the company's CFO remains confident about future product launches from other facilities.

USFDA Observations for Alkem Labs' Baddi Unit - 10 Apr, 2024

The US FDA has issued ten procedural observations to Alkem Laboratories' Baddi unit, including cleanliness and procedural errors. Shares of the company are trading slightly higher.

Alkem Laboratories Investigated by DGGI for Tax Credit and Exemption Issues - 02 Apr, 2024

The Directorate General of GST Intelligence (DGGI) is investigating Alkem Laboratories in two separate cases related to input tax credit and tax exemption issues. The company denies any wrongdoing and says it will settle fake input tax credit cases legally. The stock opened higher but closed lower, trading down 0.23% at Rs 4,993.15.

USFDA Inspection Results in Observations for Alkem Labs - 28 Mar, 2024

Alkem Laboratories' shares fell by nearly 3% after the US Food and Drug Administration (USFDA) issued a Form 483 with 10 observations for its manufacturing facility located in Baddi, Himachal Pradesh. The company received no data integrity observation and stated that the inspection was part of routine business operations. However, technical analysis suggests potential upside targets of 5200 and 5220.

Alkem Labs Receives Observations from US FDA Post Inspection - 27 Mar, 2024

Alkem Laboratories has received 10 observations from the US FDA following an inspection of its Baddi facility. The company stated that this is a routine business operation and will respond with a detailed plan within the stipulated timeline. Bernstein has maintained its outperform and underperform ratings on major pharmaceutical companies, including Alkem Laboratories.

Jan Aushadhi Scheme Dominates India's Rs 10,000-Crore Generics Market - 19 Mar, 2024

The Indian generics market worth Rs 10,000 crore is dominated by Cipla, Alkem, and the Jan Aushadhi scheme. The government-run scheme aims to provide quality medicines at affordable prices, up to 90% cheaper than regular prices.